## COVID-19 Critical Intelligence Unit

### **Daily evidence digest**

23 March 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

# Neutralising antibodies after infection and vaccination, living with children and the risk of COVID-19, vaccine second-dose completion in the US

#### Peer reviewed journals featured:

- A narrative review on SARS-CoV-2 variants, immune responses and neutralisation-resistance <u>here</u>
- · Modelling studies on:
  - SARS-CoV-2 vaccination alongside physical distancing in the UK <u>here</u> and associated commentary <u>here</u>
  - Vaccination and non-pharmaceutical interventions for COVID-19 in the UK <u>here</u>
- A case report on viable SARS-CoV-2,72 days after infection in an immunocompromised patient <u>here</u>
- Observational studies on:
  - COVID-19 vaccine second-dose completion and interval between first and second doses in the US <u>here</u>
  - An association between living with children and outcomes from COVID-19 here
  - An association between sharing a household with children and the risk of COVID-19 in healthcare worker households in Scotland here
  - o A comparison of COVID-19 policies in aged care homes in Australia and the UK here
  - An association between vitamin D levels, race/ethnicity, clinical characteristics and COVID-19 test results here
  - Trends in mortality and length of stay among COVID-19 patients (April July 2020) in the US here

#### Letters and correspondence discussed:

- Neutralising antibodies against SARS-CoV-2 variants after infection and vaccination here
- A proposal for free licensing of vaccines to end the COVID-19 crisis <u>here</u>
- Safety of mRNA SARS-CoV-2 vaccines for patients with rheumatic musculoskeletal disease <u>here</u>
- Early antibody response in kidney transplant recipients after first dose of mRNA vaccine here



#### Pre-peer review articles featured:

- The effect of vaccination on transmission of COVID-19 here
- The indirect health impacts of COVID-19 restrictions <u>here</u>
- Evidence for antibody as a protective correlate for COVID-19 vaccines here
- Information about COVID-19 vaccine effectiveness and its impact on behavioural intentions here
- The risk of reinfection after seroconversion to SARS-CoV-2 here
- Development and validation of tools to monitor post-acute COVID-19 syndrome here
- Long-term outcomes in COVID-19 patients associated with neurological complications here

#### **Guidance and reports**

- The Organisation for Economic Cooperation and Development released a report on global access to COVID-19 vaccines here
- The Australian Techincal Advisory Group on Immunisation (ATAGI) released a statement and clinical guidance on AstraZeneca COVID-19 vaccine safety <a href="here">here</a>
- The Therapeutic Goods Administration (TGA) released updates on AstraZeneca vaccine <a href="here">here</a>, here</a> and <a href="here">here</a>

#### **News and blogs**

- Stronger warnings are needed to curb socialising after vaccination here
- Influenza vaccination in 2021 <u>here</u>
- · Lateral flow tests and mass testing in schools in the UK here
- Sputnik V and other Russian vaccines here
- Protecting society from pandemics and politicians <u>here</u>
- Balancing monitoring for adverse events with confidence in vaccines <u>here</u>
- Increased risk of mortality in patients infected with B.1.1.7 (UK / Kent) variant here
- The medical establishment 'is failing the UK public' on COVID-19 here

Click here to subscribe to the daily evidence digest.

